Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 12/2015

01-12-2015 | Women’s Mental Health (CN Epperson, Section Editor)

Diagnosis and Treatment of Anxiety in the Aging Woman

Authors: Andrew M. Siegel, Sarah B. Mathews

Published in: Current Psychiatry Reports | Issue 12/2015

Login to get access

Abstract

The peri- and postmenopausal periods represent a window of vulnerability for emergence of anxiety symptoms and disorders in the life cycle of adult women. Compared to depression, anxiety symptoms and disorders remain largely unexplored during this phase of a woman’s life, despite the significant impact on quality of life if not diagnosed and treated. Here, we review the literature to present our current understanding of the epidemiology, causal factors, diagnosis, and treatment of anxiety in the aging woman.
Literature
1.
Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol. 2003;158(4):347–56.CrossRefPubMed
2.
Sagsoz N, Oguzturk O, Bayram M, Kamaci M. Anxiety and depression before and after the menopause. Arch Gynecol Obstet 264(4):199–202.
3.
Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Mariella A, Mitchell S. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause. 2008;15(2):223–32. doi:10.​1097/​gme.​0b013e3181450fc2​.CrossRefPubMed
4.
5.
Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry. 2002;63 Suppl 14:4–8.PubMed
6.
Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52(3):345–56.CrossRefPubMed
7.
Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women’s experience of the menopause. Br J Obstet Gynaecol. 1996;103(10):1025–8.CrossRefPubMed
8.•
Bromberger JT, Kravitz HM, Chang Y, Randolph JF, Jr., Avis NE, Gold EB et al. Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation. Menopause 20(5):488–95. In this 10-year, longitudinal, multi-site study involving 2956 women aged 42–52 at study entry, women with low levels of anxiety at baseline were more likely to report high anxiety at perimenopause or postmenopause than at premenopause.
9.
Hunter MS. Psychological and somatic experience of the menopause: a prospective study [corrected]. Psychosom Med. 1990;52(3):357–67.CrossRefPubMed
10.
Matthews KA, Wing RR, Kuller LH, Meilahn EN, Kelsey SF, Costello EJ, et al. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. J Consult Clin Psychol. 1990;58(3):345–51.CrossRefPubMed
11.
Juang KD, Wang SJ, Lu SR, Lee SJ, Fuh JL. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 52(2):119–26.
12.
Seritan AL, Iosif AM, Park JH, Deatherage H and D, Sweet RL, Gold EB. Self-reported anxiety, depressive, and vasomotor symptoms: a study of perimenopausal women presenting to a specialized midlife assessment center. Menopause 17(2):410–5.
13.
Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 111(1):127–36.
14.
Greenblum CA, Rowe MA, Neff DF, Greenblum JS. Midlife women: symptoms associated with menopausal transition and early postmenopause and quality of life. Menopause 20(1):22–7.
15.
Woods NF, Mitchell ES. Symptom interference with work and relationships during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause 18(6):654–61.
16.
17.
Samuelsson G, McCamish-Svensson C, Hagberg B, Sundstrom G, Dehlin O. Incidence and risk factors for depression and anxiety disorders: results from a 34-year longitudinal Swedish cohort study. Aging Ment Health. 2005;9(6):571–5. doi:10.​1080/​1360786050019359​1.CrossRefPubMed
18.
19.
Lenze EJ, Mulsant BH, Shear MK, Schulberg HC, Dew MA, Begley AE, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry. 2000;157(5):722–8.CrossRefPubMed
20.
21.
22.
23.
24.•
Norton J, Ancelin ML, Stewart R, Berr C, Ritchie K, Carriere I. Anxiety symptoms and disorder predict activity limitations in the elderly. J Affect Disord. 2012;141(2–3):276–85. doi:10.​1016/​j.​jad.​2012.​04.​002. In this study of 1581 community-dwelling persons over 65 years of age, anxiety symptoms and disorder were independently associated with activity limitations. CrossRefPubMed
25.
Smoller JW, Pollack MH, Wassertheil-Smoller S, Barton B, Hendrix SL, Jackson RD, et al. Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women’s Health Initiative. Arch Intern Med. 2003;163(17):2041–50. doi:10.​1001/​archinte.​163.​17.​2041.CrossRefPubMed
26.
Eaton W DA, Weissman M. Psychiatric disorders in America. Free Press; 1991.
27.
Amin Z, Gueorguieva R, Cappiello A, Czarkowski KA, Stiklus S, Anderson GM, et al. Estradiol and tryptophan depletion interact to modulate cognition in menopausal women. Neuropsychopharmacol: Off Public Am Coll Neuropsychopharmacol. 2006;31(11):2489–97. doi:10.​1038/​sj.​npp.​1301114.CrossRef
28.••
Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacol : Off Public Am Coll Neuropsychopharmacol. 2006;31(6):1097–111. doi:10.​1038/​sj.​npp.​1301067. This review highlights recent findings on the effects of estrogen on anxiety and depression in women and animal models.
29.
30.
Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric. 2001;4(3):243–9.CrossRefPubMed
31.
32.••
Gordon JL, Girdler SS, Meltzer-Brody SE, Stika CS, Thurston RC, Clark CT, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry. 2015;172(3):227–36. doi:10.​1176/​appi.​ajp.​2014.​14070918. This conceptual review posits a novel model candidate in the etiology of depression with onset in the menopausal transition, involving alterations in GABA-ergic tone and HPA axis dysfunction. CrossRefPubMed
33.
34.
Rodriguez-Landa JF, Contreras CM, Bernal-Morales B, Gutierrez-Garcia AG, Saavedra M. Allopregnanolone reduces immobility in the forced swimming test and increases the firing rate of lateral septal neurons through actions on the GABAA receptor in the rat. J Psychopharmacol. 2007;21(1):76–84. doi:10.​1177/​0269881106064203​.CrossRefPubMed
35.
Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav. 1993;45(2):423–8.CrossRefPubMed
36.
Morrow AL, Suzdak PD, Paul SM. Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. Eur J Pharmacol. 1987;142(3):483–5.CrossRefPubMed
37.•
Epperson CN, Sammel MD, Freeman EW. Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab. 2013;98(9):3829–38. doi:10.​1210/​jc.​2013-1808. This longitudinal, 14-year population-based cohort study found a significant decline in delayed verbal recall early in the menopausal transition and decline in immediate verbal recall late in the transition. PubMedCentralCrossRefPubMed
38.
39.
Sullivan ME, Fugate Woods N. Midlife women’s attributions about perceived memory changes: observations from the Seattle Midlife Women’s Health Study. J Womens Health Gend Based Med. 2001;10(4):351–62. doi:10.​1089/​1524609017502696​70.CrossRef
40.•
Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause. 2011;18(5):542–8. doi:10.​1097/​gme.​0b013e3181fcafd6​. In this double-blind, placebo-controlled crossover study involving 16 women with complaints of midlife-onset memory and concentration/attention difficulties, atomoxetine was found to be superior to placebo in subjective improvement in these symptoms. PubMedCentralCrossRefPubMed
41.
Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, et al. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology. 2015;232(16):3091–100.CrossRefPubMed
42.
Parry IA-MaBL. Women’s mental health. Guilford Press; 2002.
43.
44.•
Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879–88. doi:10.​1017/​S003329171100016​X. In this study of 221 African-American and Caucasian women, ages 42–52, who were premenopausal at entry, participants were two to four times more likely to experience a major depressive episode during peri-menopause or early post-menopause compared to premenopause. PubMedCentralCrossRefPubMed
45.
Sommer B, Avis N, Meyer P, Ory M, Madden T, Kagawa-Singer M, et al. Attitudes toward menopause and aging across ethnic/racial groups. Psychosom Med. 1999;61(6):868–75.CrossRefPubMed
46.
47.
Palmer BW, Jeste DV, Sheikh JI. Anxiety disorders in the elderly: DSM-IV and other barriers to diagnosis and treatment. J Affect Disord. 1997;46(3):183–90.CrossRefPubMed
48.
Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006;13(5):780–6. doi:10.​1097/​01.​gme.​0000240633.​46300.​fa.CrossRefPubMed
49.
50.
51.
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. doi:10.​1001/​archinte.​163.​22.​2716.CrossRefPubMed
52.
Fernandez L, Cassagne-Pinel C. Benzodiazepine addiction and symptoms of anxiety and depression in elderly subjects. Encéphale. 2001;27(5):459–74.PubMed
53.
Hallström C. Benzodiazepine dependence. Oxford University Press; 1993.
54.
Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc. 2000;48(7):811–6.CrossRefPubMed
55.
de Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.CrossRef
56.
57.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMed
58.
Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005;66(4):455–68.CrossRefPubMed
59.
60.
Kelly R, Zatzick D, Anders T. The detection and treatment of psychiatric disorders and substance use among pregnant women cared for in obstetrics. Am J Psychiatry. 2001;158(2):213–9.CrossRefPubMed
Metadata
Title
Diagnosis and Treatment of Anxiety in the Aging Woman
Authors
Andrew M. Siegel
Sarah B. Mathews
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 12/2015
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-015-0636-3

Other articles of this Issue 12/2015

Current Psychiatry Reports 12/2015 Go to the issue

Sleep Disorders (P Gehrman, Section Editor)

Circadian Clocks as Modulators of Metabolic Comorbidity in Psychiatric Disorders

Sleep Disorders (P Gehrman, Section Editor)

Sleep, Cognition and Dementia

Sleep Disorders (P Gehrman, Section Editor)

Chronobiological Therapy for Mood Disorders

Psychiatry in the Digital Age (JS Luo, Section Editor)

A Twitter Education: Why Psychiatrists Should Tweet

Genetic Disorders (W Berrettini, Section Editor)

Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for “Food Addiction”?